Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant increase in stock price, rising over 7% following the announcement of a distribution and supply agreement with PT Ferron Pharmaceuticals for its innovative drug BRIMOCHOL PF, aimed at treating presbyopia in the Indonesian market [1] Group 1: Company Developments - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron Pharmaceuticals for BRIMOCHOL PF, granting PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia [1] - The agreement includes an upfront payment to Zhaoke Ophthalmology, along with potential milestone payments based on certain achievements [1] Group 2: Product and Regulatory Updates - BRIMOCHOL PF is an innovative drug developed by Tenpoint Therapeutics, which has had its new drug application accepted by the U.S. FDA, with a PDUFA date set for January 28, 2026 [1]
兆科眼科-B涨超7% 与印尼药企PT Ferron就分销老花眼药达成协议